The Experts below are selected from a list of 2667 Experts worldwide ranked by ideXlab platform
Giovanni Zuliani - One of the best experts on this subject based on the ideXlab platform.
-
bilateral strio pallido dentate calcinosis fahr s disease report of seven cases and revision of literature
BMC Neurology, 2016Co-Authors: E Savino, Cecilia Soavi, Eleonora Capatti, Massimo Borrelli, Giovanni Battista Vigna, Angelina Passaro, Giovanni ZulianiAbstract:Fahr’s disease is rare a neurodegenerative idiopathic condition characterized by symmetric and bilateral calcifications of basal ganglia, usually associated with progressive neuropsychiatric dysfunctions and movement disorders. The term “Fahr’s Syndrome” is used in presence of calcifications secondary to a specific cause, but the variability of etiology, pathogenesis, and clinical picture underlying this condition have raised the question of the real existence of a Syndrome. Several classifications based on the etiology, the location of brain calcifications and the clinical presentation have been proposed. Here we describe seven clinical cases of basal ganglia calcifications, in order to search for pathognomonic features and correlations between clinical picture and imaging findings. The patients came to our attention for different reasons (most of them for memory/behavior disturbances); all underwent neuro-psychologic evaluation and neuro-imaging. All patients showed variable degrees of deterioration in cognitive function; anxiety and depression were frequent too, and resistant to treatment in all cases. Less frequent, but severe if present, were psychotic symptoms, with different grade of structure and emotional involvement, and always resistant to treatment. We observed only few cases of Extrapyramidal disorders related to the disease itself; anyway, mild Extrapyramidal Syndrome occurred quite frequently after treatment with antipsychotics. Based on these findings we discourage the use of the term “Fahr’s Syndrome”, and suggest to refer to Idiopathic or Secondary basal ganglia calcification. Unlike early onset forms (idiopathic or inherited), the clinical presentation of late onset form and Secondary basal ganglia calcification seems to be really heterogeneous. Case–control studies are necessary to determine the actual significance of basal ganglia calcification in the adult population and in the elderly, in cognitive, physical and emotional terms.
Mark S Kleven - One of the best experts on this subject based on the ideXlab platform.
-
comparative pharmacology of antipsychotics possessing combined dopamine d2 and serotonin 5 ht1a receptor properties
Psychopharmacology, 2011Co-Authors: Adrian Newmantancredi, Mark S KlevenAbstract:Rationale There is increasing interest in antipsychotics intended to manage positive symptoms via D2 receptor blockade and improve negative symptoms and cognitive deficits via 5-HT1A activation. Such a strategy reduces side-effects such as the Extrapyramidal Syndrome (EPS), weight gain, and autonomic disturbance liability.
-
comparative pharmacology of antipsychotics possessing combined dopamine d2 and serotonin 5 ht1a receptor properties
Psychopharmacology, 2011Co-Authors: Adrian Newmantancredi, Mark S KlevenAbstract:Rationale There is increasing interest in antipsychotics intended to manage positive symptoms via D2 receptor blockade and improve negative symptoms and cognitive deficits via 5-HT1A activation. Such a strategy reduces side-effects such as the Extrapyramidal Syndrome (EPS), weight gain, and autonomic disturbance liability.
Yong Sik Kim - One of the best experts on this subject based on the ideXlab platform.
-
diminished neurocardiac dynamics associated with antipsychotic induced Extrapyramidal Syndrome
European Neuropsychopharmacology, 2006Co-Authors: Jonghoon Kim, Kyungtae Park, Yong Min Ahn, Kyu Young Lee, Seung Ae Yang, Yong Sik KimAbstract:The relationship between antipsychotic-induced Extrapyramidal Syndrome (EPS) and the autonomic neurocardiac function was examined in 57 schizophrenic patients treated with atypical antipsychotics. Comprehensive assessments of EPS and heart rate dynamics were performed. There was a significant negative correlation of non-hypokinetic parkinsonism, akathisia, and dyskinesia with several linear and novel non-linear heart rate dynamics measures, suggesting reduced neurocardiac dynamics associated with some forms of EPS. Assessment of heart rate dynamics may be useful for the detection of these adverse effects and may serve as a useful non-invasive method providing a dynamic window into the alterations of complex neuronal activity.
Rui Gao - One of the best experts on this subject based on the ideXlab platform.
-
pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on Extrapyramidal Syndrome in schizophrenia
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2010Co-Authors: Qinghe Xing, Rui Gao, Yonglan Zheng, Tingwei Guo, Yifeng Yang, Jixia Liu, Aiping Zhang, Xinzhi Zhao, Jian Zhou, Lei WangAbstract:A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced Extrapyramidal Syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p=0.00404; genotype-wise: adjusted p=0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p=0.0085; for haplotype C-A-C: p=0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.
-
association of drd2 polymorphisms and chlorpromazine induced Extrapyramidal Syndrome in chinese schizophrenic patients
Acta Pharmacologica Sinica, 2006Co-Authors: Rui Gao, Qinghe Xing, Yifeng Shen, Guoyin FengAbstract:Extrapyramidal Syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients. We identified seven SNP(single nucleotidepolymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction). Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups. Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
Qinghe Xing - One of the best experts on this subject based on the ideXlab platform.
-
pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on Extrapyramidal Syndrome in schizophrenia
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2010Co-Authors: Qinghe Xing, Rui Gao, Yonglan Zheng, Tingwei Guo, Yifeng Yang, Jixia Liu, Aiping Zhang, Xinzhi Zhao, Jian Zhou, Lei WangAbstract:A number of studies have investigated the effectiveness of the dopamine transporter (SLC6A3) Gene as an antipsychotic target. However, the focus has mainly been on a 40-bp variable number of a tandem repeat (VNTR) in the 3'-region and results have been inconsistent. To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced Extrapyramidal Syndrome (EPS) in the Chinese schizophrenia population. Six polymorphisms across the whole region of this gene were analyzed, namely rs2652511 (T-844C) and rs2975226 (T-71A) in the 5'-regulatory region, rs2963238 (A1491C) in intron 1, a 30-bp VNTR in intron 8, rs27072 and the 40-bp VNTR in the 3'-region. We found that the polymorphic marker, rs2975226, showed significant association of allele and genotype frequencies with response to clozapine (allele-wise: adjusted p=0.00404; genotype-wise: adjusted p=0.024), and that patients with the T allele had a better response to the drug. The haplotype block constructed from the first three markers near the 5'-region showed significant association with response to clozapine (for haplotype T-T-A: p=0.0085; for haplotype C-A-C: p=0.0092). We did not identify any significant association of the six genetic variants or haplotypes with EPS after Bonferoni correction. Our findings suggest that the 5'-regulatory region of SLC6A3 plays an important role in response to clozapine and that its role in EPS needs to be replicated in a large-scale well designed study.
-
association of drd2 polymorphisms and chlorpromazine induced Extrapyramidal Syndrome in chinese schizophrenic patients
Acta Pharmacologica Sinica, 2006Co-Authors: Rui Gao, Qinghe Xing, Yifeng Shen, Guoyin FengAbstract:Extrapyramidal Syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor. Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression. In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients. We identified seven SNP(single nucleotidepolymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks. The alleles of all loci were determined by PCR (polymerase chain reaction). Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study. No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups. Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia. Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
